Praxis Precision Medicines Surges on Positive Study Results and FDA Progress

Praxis Precision Medicines shares are trading higher after announcing positive results from the EMBOLD study for relutrigine in epileptic encephalopathies and a successful pre-NDA meeting with the FDA for ulixacaltamide in essential tremor.